Natalizumab in Crohn’s Disease: Results From a US Tertiary Inflammatory Bowel Disease Center
Natalizumab in Crohn’s Disease: Results From a US Tertiary Inflammatory Bowel Disease Center
About this item
Full title
Author / Creator
Publisher
England: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
England: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center.
Retrospective case review of patients with CD receiving nata...
Alternative Titles
Full title
Natalizumab in Crohn’s Disease: Results From a US Tertiary Inflammatory Bowel Disease Center
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1312176492
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1312176492
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1097/MIB.0b013e31827eea78
